Articles Tagged With: SAEM
-
Pharmacology Watch
GlaxoSmithKline's rosiglitazone (Avandia) will receive a black box warning by the FDA because of concerns over heart failure associated with use of the drug.
Browse by Speciality Area
All Access Subscription
Get unlimited access to our full publication and article library.
Get Access NowInterested in Group Sales? Learn more